1395322-99-2

Upstream product

• 1395322-86-7 2-(2-fluoro-4-nitrophenyl)-5-oxohexahydrocyclopenta[c]pyrrole 
• 1395322-88-9 2-(4-amino-2-fluorophenyl)-hexahydro-1H-spiro[cyclopenta[c]pyrrole-5,2'-[1,3]dioxolane] 
• 1395322-90-3 (5R)-3-(3-fluoro-4-(tetrahydro-1H-spiro[cyclopenta[c]pyrrole-5,2'-[1,3]dioxolane]-2(3H)-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one 
• 1417820-60-0 2-[2-fluoro-4-[(5R)-5-[[(methylsulfonyl)oxy]methyl]-2-oxo-3-oxazolidinyl]phenyl]-hexahydro-1H-spiro[cyclopenta[c]pyrrole-5,2'-[1,3]dioxolane] 
• 1395322-91-4 (5R)-5-(azidomethyl)-3-(3-fluoro-4-(tetrahydro-1H-spiro[cyclopenta[c]pyrrole-5,2'-[1,3]dioxolane]-2(3H)-yl)phenyl)-oxazolidin-2-one 
• 1395322-93-6 (5R)-5-((1H-1,2,3-triazol-1-yl)methyl)-3-(3-fluoro-4-(tetrahydro-1H-spiro[cyclopenta[c]pyrrole-5,2'-[1,3]dioxolane]-2(3H)-yl)phenyl)oxazolidin-2-one 
• 1395322-95-8 (5R)-5-((1H-1,2,3-triazol-1-yl)methyl)-3-(3-fluoro-4-(5-oxohexahydrocyclopenta[c]pyrrol-2(1H)-yl)phenyl)oxazolidin-2-one 
• 1395322-97-0 (5R)-5-((1H-1,2,3-triazol-1-yl)methyl)-3-(3-fluoro-4-(5-(hydroxyimino)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)phenyl)oxazolidin-2-one 
• 593-56-6 N-methoxylamine hydrochloride 
• 1417820-59-7 octahydro-5-hydroxycyclopenta[c]pyrrole hydrochloride 
• 1395322-85-6 2-(2-fluoro-4-nitrophenyl)-octahydro-5-hydroxycyclopenta[c]pyrrole 
• 148404-28-8 tert-butyl 5-oxohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate 

Relevant academic research and scientific papers

OXAZOLIDINONE DERIVATIVES CONTAINING NEW BICYCLIC GROUP, HAVING ANTIBACTERIAL ACTIVITY, AND METHOD FOR TREATING PATHOGENIC BACTERIAL INFECTIONS USING THE SAME

The present invention relates to oxazolidinone derivatives containing new bicyclic group, having antibacterial activity, or a pharmaceutically acceptable salt thereof, a method for preparing the same, an antibacterial composition comprising the oxazolidinone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a method for treating an infectious disease caused by pathogen using the same. The oxazolidinone derivative or a pharmaceutically acceptable salt thereof may exhibit excellent antibacterial activity against gram positive bacteria including various resistant strains.

Synthesis and In Vitro Antibacterial Activity of Novel 3-Azabicyclo[3.3.0]octanyl Oxazolidinones

We synthesized a series of oxazolidinone-type antibacterials in which morpholine C-ring of linezolid has been modified by substituted 3-azabicyclo[3.3.0]octanyl rings. Acetamide or 1,2,3-triazole heterocycle was used as C-5 side chain of oxazolidinone. The resulting series of compounds was then screened in vitro against panel of susceptible and resistant Gram-positive, Gram-negative bacteria, and Mycobacterium tuberculosis (Mtb). Several analogs in this series exhibited potent in vitro antibacterial activity comparable or superior to linezolid against the tested bacteria. Compounds 10a, 10b, 11a, and 15a displayed highly potent activity against M. tuberculosis. Selected compound 10b showed good human microsomal stability and CYP-profile, and showed low activity against hERG channel. We synthesized a series of oxazolidinone-type antibacterials in which morpholine C-ring of linezolid has been modified by substituted 3-azabicyclo[3.3.0]octanyl rings, and acetamide or 1,2,3-triazole heterocycle was used as C-5 side chain of oxazolidinone. Several analogs in this series exhibited potent in vitro antibacterial activity comparable or superior to linezolid against panel of susceptible and resistant Gram-positive, Gram-negative bacteria and Mycobacterium tuberculosis (Mtb). Compounds 10a, 10b, 11a, and 15a displayed highly potent activity against M. tuberculosis.